Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 2
1973 1
1974 1
1975 2
1976 2
1977 4
1978 2
1979 1
1981 3
1982 1
1983 5
1984 4
1985 7
1987 4
1988 2
1989 1
1990 5
1991 7
1992 6
1993 2
1994 1
1996 2
1997 4
1998 1
1999 1
2000 1
2001 2
2002 1
2003 2
2004 2
2005 3
2006 4
2007 4
2008 4
2009 2
2010 2
2011 4
2012 5
2013 6
2014 2
2015 6
2016 5
2017 3
2018 3
2019 7
2020 7
2021 16
2022 9
2023 9
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE. Wilson WH, et al. Among authors: hegde u. J Clin Oncol. 2008 Jun 1;26(16):2717-24. doi: 10.1200/JCO.2007.13.1391. Epub 2008 Mar 31. J Clin Oncol. 2008. PMID: 18378569 Free PMC article. Clinical Trial.
Occurrence of Temporomandibular Disorders among patients undergoing treatment for Obstructive Sleep Apnoea Syndrome (OSAS) using Mandibular Advancement Device (MAD): A Systematic Review conducted according to PRISMA guidelines and the Cochrane handbook for systematic reviews of interventions.
Langaliya A, Alam MK, Hegde U, Panakaje MS, Cervino G, Minervini G. Langaliya A, et al. Among authors: hegde u. J Oral Rehabil. 2023 Dec;50(12):1554-1563. doi: 10.1111/joor.13574. Epub 2023 Aug 30. J Oral Rehabil. 2023. PMID: 37644889 Review.
Adult-onset nephrotic syndrome following coronavirus disease vaccination.
Biradar V, Konnur A, Gang S, Hegde U, Rajapurkar M, Patel H, Pandey SN, Soni S. Biradar V, et al. Among authors: hegde u. Clin Kidney J. 2021 Aug 28;15(1):168-170. doi: 10.1093/ckj/sfab153. eCollection 2022 Jan. Clin Kidney J. 2021. PMID: 35035948 Free PMC article.
Christmas disease.
Hegde U. Hegde U. Nurs Mirror Midwives J. 1976 Dec 23;143(26):31-3. Nurs Mirror Midwives J. 1976. PMID: 1050734 No abstract available.
168 results